Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II (POEMS)
This study has been terminated.
(Unusual high frequency of elevated liver function tests.)
Sponsor:
Louisiana State University Health Sciences Center in New Orleans
Collaborator:
Information provided by (Responsible Party):
Jesus Lovera MD, Louisiana State University Health Sciences Center in New Orleans
ClinicalTrials.gov Identifier:
NCT01451723
First received: October 11, 2011
Last updated: April 1, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The hypothesis is that Polyphenon E can protect brain cells in patients with Multiple Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate (a chemical that reflects the number of neurons and their metabolism) over one year between people with MS treated with Polyphenon E at a dose of 400mg twice a day and people with MS treated with a matching sugar pill.
| Condition | Intervention | Phase |
|---|---|---|
|
Multiple Sclerosis |
Drug: Polyphenon E Other: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Phase 2 Randomized Placebo Controlled Trial of Polyphenon E in MS |
Resource links provided by NLM:
Genetics Home Reference related topics:
multiple sclerosis
MedlinePlus related topics:
Multiple Sclerosis
Drug Information available for:
Camellia sinensis
U.S. FDA Resources
Further study details as provided by Louisiana State University Health Sciences Center in New Orleans:
Primary Outcome Measures:
- Rate of change in NAA levels adjusted for water content. [ Time Frame: 1 year ] [ Designated as safety issue: No ]The rate of change will be calculated using all the time points available )baseline, 6 and 12 months) using a mixed model analysis with the Log NAA as the dependent variable and water content, %grey matter, %white matter, %CSF and % lesion volume as covariates. All the voxels available for each subject where estimates have a SD <30 will be used. A spatial anysotropic exponential covariance structure will be used.
Secondary Outcome Measures:
- Brain Atrophy [ Time Frame: 1 year ] [ Designated as safety issue: No ]Difference between the two groups in brain atrophy as measured by SIENA
| Enrollment: | 18 |
| Study Start Date: | July 2011 |
| Study Completion Date: | February 2013 |
| Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Polyphenon E 400mg twice a day
Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.
|
Drug: Polyphenon E
Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
Other Names:
|
|
Placebo Comparator: Placebo
Matching placebo capsules.
|
Other: Placebo
Matching placebo capsules
|
Detailed Description:
This will be a double blind placebo controlled trial of Polyphenon E as a treatment for MS.
The primary outcome will be the changes in NAA levels over one year. Secondary outcomes will be changes in brain atrophy over one year. As an exploratory outcome we will correlate changes in NAA levels with free Plasma levels of EGCG 8 hours after the morning dose.
Exploratory outcomes include disability progression by EDSS, MS functional composite components and a cognitive test battery.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of MS by McDonald criteria
- Relapsing-remitting MS or secondary progressive MS
- Stable therapy with Copaxone, Rebif, Betaseron or Avonex 30 mcg for at least six months
- EDSS Score less than or equal to 7.0
- Ages 18-60.
Participants must have normal organ and marrow function as defined below:
- Leukocytes ≥3,000/µL
- Absolute neutrophil count ≥1,500/µL
- Platelets ≥100,000/µL
- Total bilirubin ≤local upper limit of normal
- AST (SGOT) ≤local upper limit of normal
- ALT (SGPT) ≤local upper limit of normal
- Creatinine ≤local upper limit of normal
Exclusion Criteria:
- MS relapse within the 30 days prior to enrollment
- A primary progressive form of MS.
- Previous treatment prior to study entry as follows: complete radiation ablation of the bone marrow or anti-CD4 antibody treatment (Campath) at any time; mitoxantrone, cyclophosphamide, Natalizumab or other immunomodulatory or immunosuppressant therapies except the DMT's included in the inclusion criteria and methylprednisone for relapses within prior nine months.
- History of renal or liver disease.
- Consumption of green tea or supplements containing green tea or tea extract within 30 days prior to enrollment.
- Participants may not participate in any other clinical trial involving investigational agents during the study, or within six months prior to enrolling in the study.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Polyphenon E, tea, or any of the inactive ingredients present in the active or placebo capsules, including gelatin.
- History of allergic reactions to gadolinium or any other condition contraindicated for MRI.
- Uncontrolled, clinically-relevant active illness (aside from MS) including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study
- Inability to complete the baseline MRI scan
- Pregnant women
- Any underlying predisposition to gastrointestinal bleeding (peptic ulcer disease, gastritis, diverticulitis, colitis, hemorrhoids)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01451723
Locations
| United States, Louisiana | |
| LSu Health Sciences Center | |
| New Orleans, Louisiana, United States, 70112 | |
Sponsors and Collaborators
Louisiana State University Health Sciences Center in New Orleans
Investigators
| Principal Investigator: | Jesus F Lovera, MD | LSUHSC-New Orleans |
More Information
Additional Information:
No publications provided
| Responsible Party: | Jesus Lovera MD, MD, MsPH, Louisiana State University Health Sciences Center in New Orleans |
| ClinicalTrials.gov Identifier: | NCT01451723 History of Changes |
| Other Study ID Numbers: | K23 AT004433-02, K23AT004433-02, K23AT004433 |
| Study First Received: | October 11, 2011 |
| Last Updated: | April 1, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Louisiana State University Health Sciences Center in New Orleans:
|
Multiple Sclerosis Polyphenon E Green tea EGCG |
Epigallocatechin-galleate Placebo Randomized controlled trial |
Additional relevant MeSH terms:
|
Multiple Sclerosis Sclerosis Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Pathologic Processes Epigallocatechin gallate Antioxidants |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs Antimutagenic Agents Anticarcinogenic Agents Antineoplastic Agents Therapeutic Uses Neuroprotective Agents Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 21, 2013